Abstract

Graves disease is an autoimmune condition and the main cause of hyperthyroidism. The present study consists of the analysis of the evolution after radioidine theraphy treatment in pacients with Graves' disease, wich took place at the Thyroid Dysfunction Unit of Endocrinology Division, HC-Unicamp, according to its pacients charts review. Radioidine theraphy (RIT) was indicated in 68% of the pacients (171/251), of whom 80,1% (n=137) of these cases after RIT presented definitive control of the disease with one radioidine admnistration. Therefore, the outcome of the patient related to the RIT failure was the thyroid volume according to the ultrasound and the scintigraphy uptake, and in addition, the thyroid volume was reported as a predictor factor for the failure to control hyperthyroidism.

Highlights

  • Graves’ disease is the main cause of hyperthyroidism

  • This study evaluated 251 patients diagnosed with Graves’ hyperthyroidism, in both genders, followed in the Thyroid Dysfunction Unit of Endocrinology Division, HCUnicamp

  • Radioidine theraphy was indicated in 68% (171/251) of the patients, of whom 80.1% (n = 137) of these cases presented definitive control with one radioidine admnistration

Read more

Summary

Introduction

Graves’ disease is the main cause of hyperthyroidism. This condition is associated to the presence of antibody against TSH-receptor (TRAb), which leads to an uncontrolled synthesis of T3 and T4 hormones and the thyroid hypertrophy. The therapy for Graves’ disease involves antithyroid drugs, radioidine theraphy or thyroidectomy. Radioactive iodine (RIT) is the admnistration of 131-I to promote the thyroid cells progressive necrosis and the hyperthyroidism control. Our aims were to evaluate the outcome after RIT in patients with Graves' disease, and factors associated to the success of the treatment

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.